Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semax

ACTH(4-10) analogue, Heptapeptide SEMAX

Quick Stats
Studies 172
Trials 37
Score 3
2006 pubmed 23 citations

Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.

Dolotov. Oleg V OV; Karpenko. Ekaterina A EA; Seredenina. Tamara S TS; Inozemtseva. Lyudmila S LS; Levitskaya. Natalia G NG; Zolotarev. Yuriy A YA; Kamensky. Andrey A AA; Grivennikov. Igor A IA; Engele. Juergen J; Myasoedov. Nikolay F NF

Key Findings

  • Semax binds with high affinity (KD ~2.4 nM) to sites in the rat basal forebrain.
  • Intranasal Semax at 50‑250 µg/kg raises BDNF protein in the basal forebrain within 3 hours.
  • The BDNF increase is region‑specific, not seen in the cerebellum.

Practical Outcomes

  • For biohackers, intranasal Semax could be explored as a way to boost brain BDNF and potentially enhance learning or neuroprotection, using doses in the low‑hundreds of µg per kg range as a starting point. However, the evidence is limited to rats, so human effects, safety, and optimal dosing remain uncertain and should be approached cautiously.

Summary

In rats, the peptide Semax given through the nose quickly raises levels of BDNF—a protein that supports brain plasticity—in the part of the brain that controls learning, without affecting other regions. This effect appears to come from Semax binding to specific sites in that brain area.

Abstract

The heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analogue of the N-terminal fragment (4-10) of adrenocorticotropic hormone which, after intranasal application, has profound effects on learning and memory formation in rodents and humans, and also exerts marked neuroprotective effects. A clue to the molecular mechanism underlying this neurotropic action was recently given by the observation that Semax stimulates the synthesis of brain-derived neurotrophic factor (BDNF), a potent modulator of synaptic plasticity, in astrocytes cultured from rat basal forebrain. In the present study, we investigated whether Semax affects BDNF levels in rat basal forebrain upon intranasal application of the peptide. In addition, we examined whether cell membranes isolated from this brain region contained binding sites for Semax. The binding of tritium-labelled Semax was found to be time dependent, specific and reversible. Specific Semax binding required calcium ions and was characterized by a mean+/-SEM dissociation constant (KD) of 2.4+/-1.0 nm and a BMAX value of 33.5+/-7.9 fmol/mg protein. Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain, but not in the cerebellum. These results point to the presence of specific binding sites for Semax in the rat basal forebrain. In addition, these findings indicate that the cognitive effects exerted by Semax might be associated, at least in part, with increased BDNF protein levels in this brain region.

Study Information

Provider

pubmed

Year

2006

Date

2006-04-01T00:00:00.000Z

DOI

10.1111/j.1471-4159.2006.03658.x

Citations

23

References

33